<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945109</url>
  </required_header>
  <id_info>
    <org_study_id>0094-21SOR</org_study_id>
    <nct_id>NCT04945109</nct_id>
  </id_info>
  <brief_title>Wolffia Globosa (Mankai) and Glycemic Control Among Patients With Type 2 Diabetes</brief_title>
  <official_title>The Effect of Wolffia Globosa (Mankai) on Glycemic Control Among Patients With Type 2 Diabetes; A Randomized Crossover Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ben-Gurion University of the Negev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ben-Gurion University of the Negev</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators primarily aim to explore the effect of daily additive supplementation of&#xD;
      Mankai on glucose control among participants with T2D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a major public health concern in Western societies. Type 2 diabetes is&#xD;
      associated with high morbidity and shorter life expectancy. In patients with type 2 diabetes&#xD;
      maintaining glycemic control is associated with lower rates of complications and mortality&#xD;
      associated with the disease. Thus, there is a great need to recognize nutritional elements&#xD;
      that improve glycemic control and insulin sensitivity in patients with type 2 diabetes.&#xD;
      Mankai, a strain of Wolffia globosa recently developed under controlled conditions, is&#xD;
      characterized by high protein content and good bioavailability of proteins, rich in soluble&#xD;
      fiber, vitamins (including vitamin B12), minerals (including iron and zinc), omega 3 fatty&#xD;
      acids, and polyphenols. The 18-month long DIRECT PLUS trial was a weight-loss intervention&#xD;
      conducted among 294 participants with abdominal obesity or dyslipidemia. 98 of the study&#xD;
      participants were assigned to the intervention of a green Mediterranean diet and were&#xD;
      instructed to consume four frozen cubes of Mankai daily. Main conclusions from the DIRECT&#xD;
      PLUS refer to the beneficial effect of the green-Mediterranean diet on cardiometabolic risk,&#xD;
      gut bacteria, and liver fat, with no evidence of disadvantages or adverse effects of&#xD;
      long-term Mankai consumption. In 2019, the investigators reported that among non-diabetics&#xD;
      and those with fasting glucose levels within the normal range, consuming a Mankai smoothie in&#xD;
      the evening led to lower glucose levels after the meal and lower fasting overnight compared&#xD;
      to a yogurt smoothie. The investigators now plan to explore the effect of Mankai daily&#xD;
      supplementation on post-meal glycemic response in participants with type 2 diabetes. The&#xD;
      investigators hypothesize that the addition of Mankai consumption after a meal may mitigate&#xD;
      glucose excursions compared with control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomized cross-over, 4-week trial, where participants will be allocated to start with or without daily Mankai supplementation (fresh Mankai beverage) added on top of a standardized diabetes-related healthy diet, each for two weeks. The investigators will follow postprandial and overnight glycemic response using ï¬‚ash glucose monitoring system device. Other outcomes include clinical parameters (weight, waist circumference, blood pressure), blood, urine, fecal measurements, overall appetite/ satiety, food intake consumption, symptoms, and medical treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glycemic control</measure>
    <time_frame>Through study completion, 24hours a day (continuous measurement, all day, 4 weeks)</time_frame>
    <description>Continuous glucose excursions monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Blood measured insulin (mIU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Blood measure of glucose (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Lipid profile: TC, TG, HDL, LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum liver Enzymes</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Liver enzymes: ALT, AST, GGT, ALKP (U/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota profile</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Fecal bacterial composition and richness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBC</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Complete blood cells count: red, white, differential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Weight (kg), height (cm) to calculate BMI (kg/m^2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal obesity</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Resting pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Systolic and Diastolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine markers of glucose</measure>
    <time_frame>0,2,4 weeks</time_frame>
    <description>Glucose in urine (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine markers of protein</measure>
    <time_frame>0,2,4 weeks</time_frame>
    <description>Protein in urine (mg/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire 1</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Self reports on symptoms during the intervention (yes/no questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire 2</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Self reports on appetite during the intervention (scale of 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire 3</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Self reports on satiety during the intervention (scale of 0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>questionnaire 4</measure>
    <time_frame>0, 2, 4 weeks</time_frame>
    <description>Self reports on lifestyle (daily log, self report without scale of measurement)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Mankai beverage first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of Mankai supplementation followed by two weeks of water supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mankai beverage last</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of water supplementation followed by two weeks of Mankai supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mankai beverage</intervention_name>
    <description>Recommended background healthy diet with Mankai supplementation after main meal (300 ml)</description>
    <arm_group_label>Mankai beverage first</arm_group_label>
    <arm_group_label>Mankai beverage last</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water (control)</intervention_name>
    <description>Recommended background healthy diet with water supplementation after main meal (300 ml)</description>
    <arm_group_label>Mankai beverage first</arm_group_label>
    <arm_group_label>Mankai beverage last</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age =&gt; 30 years&#xD;
&#xD;
          -  A formal diagnosis of T2D (126mg/dl fasting glucose or higher, or HbA1c=&gt;6.5%) or&#xD;
             taking T2D medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with coumadin (warfarin)&#xD;
&#xD;
          -  Advanced renal failure&#xD;
&#xD;
          -  A significant illness that might require hospitalization&#xD;
&#xD;
          -  State of pregnancy or lactation&#xD;
&#xD;
          -  Presence of active cancer or chemotherapy treatment in last three years&#xD;
&#xD;
          -  Participation in another trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Tirosh, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuclear research center Negev</name>
      <address>
        <city>Dimona</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Centre</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Zelicha H, Kaplan A, Yaskolka Meir A, Tsaban G, Rinott E, Shelef I, Tirosh A, Brikner D, Pupkin E, Qi L, Thiery J, Stumvoll M, Kloting N, von Bergen M, Ceglarek U, BlÃ¼her M, Stampfer MJ, Shai I. The Effect of Wolffia globosa Mankai, a Green Aquatic Plant, on Postprandial Glycemic Response: A Randomized Crossover Controlled Trial. Diabetes Care. 2019 Jul;42(7):1162-1169. doi: 10.2337/dc18-2319. Epub 2019 May 10.</citation>
    <PMID>31076421</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ben-Gurion University of the Negev</investigator_affiliation>
    <investigator_full_name>Iris Shai</investigator_full_name>
    <investigator_title>Prof. Iris Shai</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

